In conclusion, our results suggest that CD39+ Treg in colon adenocarcinomas are a potent immunosuppressive population, and indicate that immunotherapies aimed at targeting CD39+ Treg may be promising against colon cancer. This evidence concerns the gene ENTPD1 and colon adenocarcinoma.